Evaluation of bacterial uptake, antibacterial efficacy against Escherichia coli, and cytotoxic effects of moxifloxacin-loaded solid lipid nanoparticles

Kiymaci, Merve Eylul; Topal, Gizem Ruya; Esim, Ozgur; Bacanli, Merve; Ozkan, Cansel Kose; Erdem, Onur; Savaser, Ayhan; Ozkan, Yalcin

doi:10.2478/aiht-2022-73-3667

Abstract

Moxifloxacin (MOX) is an important antibiotic commonly used in the treatment of recurrent Escherichia coli (E. coli) infections. The aim of this study was to investigate its antibacterial efficiency when used with solid lipid nanoparticles (SNLs) and nanostructured lipid carriers (NLCs) as delivery vehicles. For this purpose we designed two SLNs (SLN1 and SLN2) and two NLCs (NLC1 and NLC2) of different characteristics (particle size, size distribution, zeta potential, and encapsulation efficiency) and loaded them with MOX to determine its release, antibacterial activity against E. coli, and their cytotoxicity to the RAW 264.7 monocyte/macrophage-like cell line in vitro. With bacterial uptake of 57.29 %, SLN1 turned out to be significantly more effective than MOX given as standard solution, whereas SLN2, NLC1, and NLC2 formulations with respective bacterial uptakes of 50.74 %, 39.26 %, and 32.79 %, showed similar activity to standard MOX. Cytotoxicity testing did not reveal significant toxicity of nanoparticles, whether MOX-free or MOX-loaded, against RAW 264.7 cells. Our findings may show the way for a development of effective lipid carriers that reduce side effects and increase antibacterial treatment efficacy in view of the growing antibiotic resistance.

References

Martinez JL, Baquero F. Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother 2000;44:1771–7. doi: 10.1128/ AAC.44.7.1771-1777.2000
Open DOI Search in Google Scholar Back to article
Boto L, Martinez JL. Ecological and temporal constraints in the evolution of bacterial genomes. Genes (Basel) 2011;2:804–28. doi: 10.3390/genes2040804
Open DOI Search in Google Scholar Back to article
Mackenzie JS, Jeggo M. The one health approach - why is it so important? Trop Med Infect Dis 2019;4(2):88. doi: 10.3390/ tropicalmed4020088
Open DOI Search in Google Scholar Back to article
Martinez JL. General principles of antibiotic resistance in bacteria. Drug Discov Today Technol 2014;11:33–9. doi: 10.1016/j. ddtec.2014.02.001
Open DOI Search in Google Scholar Back to article
World Health Organization (WHO). Antibiotic Resistance [displayed 15 March 2022]. Available at https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance
Search in Google Scholar Back to article
Yeh YC, Huang TH, Yang SC, Chen CC, Fang JY. Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: a review of recent advances. Front Chem 2020;8:286. doi: 10.3389/ fchem.2020.00286
Open DOI Search in Google Scholar Back to article
Sofowora A, Ogunbodede E, Onayade A. The role and place of medicinal plants in the strategies for disease prevention. Afr J Tradit Complement Altern Med 2013;10:210–29. doi: 10.4314/ajtcam.v10i5.2
Open DOI Search in Google Scholar Back to article
Chen CH, Lu TK. Development and challenges of antimicrobial peptides for therapeutic applications. Antibiotics (Basel) 2020;9(1):24. doi: 10.3390/antibiotics9010024
Open DOI Search in Google Scholar Back to article
Jiang Q, Chen J, Yang C, Yin Y, Yao K. Quorum sensing: a prospective therapeutic target for bacterial diseases. Biomed Res Int 2019;2019:2015978. doi: 10.1155/2019/2015978
Open DOI Search in Google Scholar Back to article
Lin DM, Koskella B, Lin HC. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther 2017;8:162–73. doi: 10.4292/wjgpt.v8.i3.162
Open DOI Search in Google Scholar Back to article
Gebreyohannes G, Nyerere A, Bii C, Sbhatu DB. Challenges of intervention, treatment, and antibiotic resistance of biofilm-forming microorganisms. Heliyon 2019;5(8):e02192. doi: 10.1016/j. heliyon.2019.e02192
Open DOI Search in Google Scholar Back to article
Arana L, Gallego L, Alkorta I. Incorporation of antibiotics into solid lipid nanoparticles: a promising approach to reduce antibiotic resistance emergence. Nanomaterials (Basel) 2021;11(5):1251. doi: 10.3390/nano11051251
Open DOI Search in Google Scholar Back to article
Duan Y, Dhar A, Patel C, Khimani M, Neogi S, Sharma P, Kumar NS, Vekariya RL. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Adv 2020;10:26777–91. doi: 10.1039/D0RA03491F
Open DOI Search in Google Scholar Back to article
Marslin G, Revina AM, Khandelwal VK, Balakumar K, Sheeba CJ, Franklin G. PEGylated ofloxacin nanoparticles render strong antibacterial activity against many clinically important human pathogens. Colloids Surf B Biointerfaces 2015;132:62–70. 10.1016/j.colsurfb.2015.04.050
Open DOI Search in Google Scholar Back to article
Sheeba CJ, Marslin G, Revina AM, Franklin G. Signaling pathways influencing tumor microenvironment and their exploitation for targeted drug delivery. Nanotechnol Rev 2014;3:123–51. doi: 10.1515/ ntrev-2013-0032
Open DOI Search in Google Scholar Back to article
Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull 2015;5:305–13. doi: 10.15171/apb.2015.043
Open DOI Search in Google Scholar Back to article
Škalko-Basnet N, Vanić Ž. Lipid-based nanopharmaceuticals in antimicrobial therapy. In: Boukherroub R, Szunerits S, Drider D, editors. Functionalized nanomaterials for the management of microbial infection. London: Elsevier; 2017. p. 111–52.
Search in Google Scholar Back to article
Severino P, De Hollanda LM, Santini A, Reis LV, Souto SB, Souto EB, Silva MA. Advances in nanobiomaterials for oncology nanomedicine. In: Grumezescu AM, editor. Nanobiomaterials in cancer therapy: Applications of nanobiomaterials. Vol. 7. Chapter 4. New York (NY): William Andrew Publishing; 2016. p. 91–115.
Search in Google Scholar Back to article
Madkhali OA. Perspectives and prospective on solid lipid nanoparticles as drug delivery systems. Molecules 2022;27(5):1543. doi: 10.3390/ molecules27051543
Open DOI Search in Google Scholar Back to article
Esim O, Hascicek C. Lipid-coated nanosized drug delivery systems for an effective cancer therapy. Curr Drug Deliv 2021;18:147–61. doi: 10.2174/1567201817666200512104441
Open DOI Search in Google Scholar Back to article
Elmowafy M, Al-Sanea MM. Nanostructured lipid carriers (NLCs) as drug delivery platform: advances in formulation and delivery strategies. Saudi Pharm J 2021;29:999–1012. doi: 10.1016/j.jsps.2021.07.015
Open DOI Search in Google Scholar Back to article
Misra S, Chopra K, Sinha VR, Medhi B. Galantamine-loaded solid-lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations. Drug Deliv 2016;23:1434–43. doi: 10.3109/10717544.2015.1089956
Open DOI Search in Google Scholar Back to article
Yasir M, Sara UVS. Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation. Acta Pharm Sin B 2014;4:454–63. doi: 10.1016/j.apsb.2014.10.005
Open DOI Search in Google Scholar Back to article
Uner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie 2006;61:375–86. PMID: 16724531
Search in Google Scholar Back to article
The National Center for Biotechnology Information (NCBI). PubChem Compound Summary for CID 152946, Moxifloxacin [displayed 15 March 2022]. Available at https://pubchem.ncbi.nlm.nih.gov/compound/Moxifloxacin
Search in Google Scholar Back to article
Guay DR. Moxifloxacin in the treatment of skin and skin structure infections. Ther Clin Risk Manag 2006;2:417–34. doi: 10.2147/ tcrm.2006.2.4.417
Open DOI Search in Google Scholar Back to article
Scholar E. Levofloxacin. In: Enna SJ, Bylund DB, editors. xPharm: The Comprehensive Pharmacology Reference. New York (NY): Elsevier; 2007. p. 1–6.
Search in Google Scholar Back to article
Wu D, Ding Y, Yao K, Gao W, Wang Y. Antimicrobial resistance analysis of clinical Escherichia coli isolates in neonatal ward. Front Pediatr 2021;9:670470. doi: 10.3389/fped.2021.670470
Open DOI Search in Google Scholar Back to article
Pinto-Alphandary H, Andremont A, Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int J Antimicrob Agents 2000;13:155–68. doi: 10.1016/ s0924-8579(99)00121-1
Open DOI Search in Google Scholar Back to article
Wong JP, Cherwonogrodzky JW, Di Ninno VL, De la Cruz R, Saravolac EG. Liposome-encapsulates ciprofloxacin for the prevention and treatment of infectious diseases caused by intracellular pathogens. In: Shek PN, editor. Liposomes in biomedical applications. Amsterdam: Harwood Academic Publishers; 1995. p. 105–20.
Search in Google Scholar Back to article
Mussi SV, Sawant R, Perche F, Oliveira MC, Azevedo RB, Ferreira LA, Torchilin VP. Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells. Pharm Res 2014;31:1882–92. doi: 10.1007/s11095-013-1290-2
Open DOI Search in Google Scholar Back to article
Topal GR, Kiymaci ME, Özkan Y. Preparation and in vitro characterization of vancomycin loaded PLGA nanoparticles for the treatment of Enterococcus faecalis infections. J Fac Pharm Ankara 2022;46:350–63. doi: 10.33483/jfpau.1073081
Open DOI Search in Google Scholar Back to article
Yurtdaş Kırımlıoğlu G, Özer S, Büyükköroğlu G, Yazan Y. Formulation and in vitro evaluation of moxifloxacin hydrochloride-loaded polymeric nanoparticles for ocular application. Lat Am J Pharm 2018;37:1850–62.
Search in Google Scholar Back to article
Savaser A, Esim O, Kurbanoglu S, Ozkan SA, Özkan Y. Current perspectives on drug release studies from polymeric nanoparticles. In: Grumezescu AM, editors. Organic materials as smart nanocarriers for drug delivery. New York (NY): William Andrew Publishing; 2018. p. 101–45.
Search in Google Scholar Back to article
The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters version 12.0, valid from 2022-01-01 [displayed 15 March 2022]. Available at https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf
Search in Google Scholar Back to article
Bacanli M, Esim MO, Erdogan H, Sarper M, Erdem O, Özkan Y. Evaluation of cytotoxic and genotoxic effects of paclitaxel-loaded PLGA nanoparticles in neuroblastoma cells. Food Chem Toxicol 2021;154:112323. doi: 10.1016/j.fct.2021.112323
Open DOI Search in Google Scholar Back to article
Sarwar A, Katas H, Zin NM. Antibacterial effects of chitosan– tripolyphosphate nanoparticles: impact of particle size molecular weight. J Nanoparticle Res 2014;16:2517. doi: 10.1007/s11051-014-2517-9
Open DOI Search in Google Scholar Back to article
Martins S, Tho I, Reimold I, Fricker G, Souto E, Ferreira D, Brandl M. Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies. Int J Pharm 2012;439:49–62. doi: 10.1016/j.ijpharm.2012.09.054
Open DOI Search in Google Scholar Back to article
Schöler N, Olbrich C, Tabatt K, Müller RH, Hahn H, Liesenfeld O. Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. Int J Pharm 2001;221:57–67. doi: 10.1016/s0378-5173(01)00660-3
Open DOI Search in Google Scholar Back to article
Lages EB, Fernandes RS, Silva JO, de Souza AM, Cassali GD, de Barros ALB, Miranda Ferreira LA. Co-delivery of doxorubicin, docosahexaenoic acid, and alpha-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity. Biomed Pharmacother 2020;132:110876. doi: 10.1016/j.biopha.2020.110876
Open DOI Search in Google Scholar Back to article
Das S, Ng WK, Kanaujia P, Kim S, Tan RB. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf B Biointerfaces 2011;88:483–9. doi: 10.1016/j. colsurfb.2011.07.036
Open DOI Search in Google Scholar Back to article
Amasya G, Bakar-Ates F, Wintgens V, Amiel C. Layer by layer assembly of core-corona structured solid lipid nanoparticles with beta-cyclodextrin polymers. Int J Pharm 2021;592:119994. doi: 10.1016/j. ijpharm.2020.119994
Open DOI Search in Google Scholar Back to article
Singh S, Dobhal AK, Jain A, Pandit JK, Chakraborty S. Formulation and evaluation of solid lipid nanoparticles of a water soluble drug: Zidovudine. Chem Pharm Bull (Tokyo) 2010;58:650–5. doi: 10.1248/ cpb.58.650
Open DOI Search in Google Scholar Back to article
Al-Qushawi A, Rassouli A, Atyabi F, Peighambari SM, Esfandyari-Manesh M, Shams GR, Yazdani A. Preparation and characterization of three tilmicosin-loaded lipid nanoparticles: physicochemical properties and in-vitro antibacterial activities. Iran J Pharm Res 2016;15:663–76. PMCID:PMC5316245
Search in Google Scholar Back to article
Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002;242:121–8. doi: 10.1016/s0378-5173(02)00180-1
Open DOI Search in Google Scholar Back to article
Ebrahimi S, Farhadian N, Karimi M, Ebrahimi M. Enhanced bactericidal effect of ceftriaxone drug encapsulated in nanostructured lipid carrier against gram-negative Escherichia coli bacteria: drug formulation, optimization, and cell culture study. Antimicrob Resist Infect Control 2020;9(1):28. doi: 10.1186/s13756-020-0690-4
Open DOI Search in Google Scholar Back to article
Kumar S, Bhanjana G, Kumar A, Taneja K, Dilbaghi N, Kim KH. Synthesis and optimization of ceftriaxone-loaded solid lipid nanocarriers. Chem Phys Lipids 2016;200:126–32. doi: 10.1016/j. chemphyslip.2016.09.002
Open DOI Search in Google Scholar Back to article
Esim O, Sarper M, Ozkan CK, Oren S, Baykal B, Savaser A, Ozkan Y. Effect simultaneous delivery with P-glycoprotein inhibitor and nanoparticle administration of doxorubicin on cellular uptake and in vitro anticancer activity. Saudi Pharm J 2020;28:465–72. doi: 10.1016/j. jsps.2020.02.008
Open DOI Search in Google Scholar Back to article
Akbar N, Gul J, Siddiqui R, Shah MR, Khan NA. Moxifloxacin and sulfamethoxazole-based nanocarriers exhibit potent antibacterial activities. Antibiotics (Basel) 2021;10(8):964. doi: 10.3390/ antibiotics10080964
Open DOI Search in Google Scholar Back to article
Kisich KO, Gelperina S, Higgins MP, Wilson S, Shipulo E, Oganesyan E, Heifets L. Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis. Int J Pharm 2007;345:154–62. doi: 10.1016/j. ijpharm.2007.05.062
Open DOI Search in Google Scholar Back to article
Tshweu LL, Shemis MA, Abdelghany A, Gouda A, Pilcher LA, Sibuyi NR, Meyer M, Dube A, Balogun MO. Synthesis, physicochemical characterization, toxicity and efficacy of a PEG conjugate and a hybrid PEG conjugate nanoparticle formulation of the antibiotic moxifloxacin. RSC Adv 2020;10:19770–80. doi: 10.1039/C9RA10872F
Open DOI Search in Google Scholar Back to article

Evaluation of bacterial uptake, antibacterial efficacy against Escherichia coli, and cytotoxic effects of moxifloxacin-loaded solid lipid nanoparticles

Abstract

Paradigm

My account